Oxford Biomedica sees new investment for manufacturing; Twist gets a partner to help build out discovery libraries
Oxford Biomedica has landed some new cash.
The British gene and cell therapy biotech announced Wednesday it has secured an investment “just over” £50 million from the Serum Institute of India’s investment arm. Funds are expected to help Oxford Biomedica build out its 84,000-square-foot manufacturing facility and bring online several independent suites by mid-2023.
“Serum Institute of India has played a big part in the fight against COVID-19, as have we, and we look forward to a strong and collaborative relationship,” CEO John Dawson said in a statement. “This investment will allow us to expand capacity at Oxbox at a time when our business development pipeline has never looked stronger.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.